Aduro BioTech (ADRO) Received its Third Buy in a Row


After H.C. Wainwright and Oppenheimer gave Aduro BioTech (NASDAQ: ADRO) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Chris Shibutani maintained a Buy rating on Aduro BioTech yesterday. The company’s shares closed yesterday at $4.24, close to its 52-week low of $3.69.

According to TipRanks.com, Shibutani is a 2-star analyst with an average return of 1.0% and a 37.2% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and United Therapeutics.

Aduro BioTech has an analyst consensus of Strong Buy, with a price target consensus of $16.10, implying a 279.7% upside from current levels. In a report issued on October 30, Oppenheimer also reiterated a Buy rating on the stock with a $10 price target.

.

See today’s analyst top recommended stocks >>

Based on Aduro BioTech’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $23.15 million. In comparison, last year the company had a GAAP net loss of $24.52 million.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts